ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,328 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1Phase 2Burkitt LymphomaDouble-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Biopsy ProcedureBiospecimen CollectionComputed Tomography+3 more

National Cancer Institute (NCI)50 participants4 sites · United StatesCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Phase 2Non-Small Cell Lung Cancer

Benmelstobart

Shanghai Pulmonary Hospital, Shanghai, China62 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Phase 2Pancreatic Ductal Adenocarcinoma

Neoadjuvant Chemotherapy (NAC)Immunotherapy (pembrolizumab)Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

The University of Texas Health Science Center, Houston24 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

Phase 1Phase 2DCSZ11Solid TumorsHNSCC

Low Dose DCSZ11Medium Dose DCSZ11High Dose DCSZ11+1 more

West China Hospital9 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Glutamate Inhibitors in Glioblastoma

Phase 1Phase 2Glioblastoma

GabapentinSulfasalazineMemantine+2 more

University of Zurich120 participants1 site · SwitzerlandCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Phase 1Phase 2Solid Tumors With FGFR2 Alterations, Adult

3HP-2827

3H (Suzhou) Pharmaceuticals Co., Ltd.130 participants2 sites · ChinaCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Biopsy ProcedureBiospecimen CollectionComputed Tomography+8 more

National Cancer Institute (NCI)500 participants27 sites · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1Phase 2Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)

DaraxonrasibElironrasibZoldonrasib+5 more

Revolution Medicines, Inc.370 participants5 sites · United StatesCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Phase 2Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell Carcinoma

Biospecimen CollectionCarboplatinCemiplimab+6 more

National Cancer Institute (NCI)180 participants78 sites · United StatesCompletes Feb 2033

Compare CT.gov Full analysis →

Recruiting

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2Locally Advanced Cervical Cancer

ZimberelimabAlbumin-bound PaclitaxelCisplatin

Tang-Du Hospital20 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Phase 2Hepatocellular Carcinoma (HCC)

LenalidomideTargeted TherapyImmune Checkpoint Inhibitors

Shunda Du32 participants1 site · ChinaCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Phase 2Prostate Cancer Metastatic

PembrolizumabCarboplatinCabazitaxel

Fundacion Oncosur42 participants1 site · SpainCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma

PembrolizumabAldesleukin

National Cancer Institute (NCI)78 participants1 site · United StatesCompletes Sep 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2Hematological Malignancies

Talquetamab

Janssen Research & Development, LLC510 participants78 sites · United States, Belgium, ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Phase 2Breast CancerAdjuvant TreatmentEarly Stage Breast Cancer

SwitchGuideline Directed Intervention (GDI)

Dartmouth-Hitchcock Medical Center62 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 6,328

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,328 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1Phase 2Burkitt LymphomaDouble-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Biopsy ProcedureBiospecimen CollectionComputed Tomography+3 more

National Cancer Institute (NCI)50 participants4 sites · United StatesCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Phase 2Non-Small Cell Lung Cancer

Benmelstobart

Shanghai Pulmonary Hospital, Shanghai, China62 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Phase 2Pancreatic Ductal Adenocarcinoma

Neoadjuvant Chemotherapy (NAC)Immunotherapy (pembrolizumab)Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)

The University of Texas Health Science Center, Houston24 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

Phase 1Phase 2DCSZ11Solid TumorsHNSCC

Low Dose DCSZ11Medium Dose DCSZ11High Dose DCSZ11+1 more

West China Hospital9 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Glutamate Inhibitors in Glioblastoma

Phase 1Phase 2Glioblastoma

GabapentinSulfasalazineMemantine+2 more

University of Zurich120 participants1 site · SwitzerlandCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Phase 1Phase 2Solid Tumors With FGFR2 Alterations, Adult

3HP-2827

3H (Suzhou) Pharmaceuticals Co., Ltd.130 participants2 sites · ChinaCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Biopsy ProcedureBiospecimen CollectionComputed Tomography+8 more

National Cancer Institute (NCI)500 participants27 sites · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1Phase 2Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)

DaraxonrasibElironrasibZoldonrasib+5 more

Revolution Medicines, Inc.370 participants5 sites · United StatesCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Biospecimen CollectionCarboplatinCemiplimab+6 more

National Cancer Institute (NCI)180 participants78 sites · United StatesCompletes Feb 2033

Compare CT.gov Full analysis →

Recruiting

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2Locally Advanced Cervical Cancer

ZimberelimabAlbumin-bound PaclitaxelCisplatin

Tang-Du Hospital20 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Phase 2Hepatocellular Carcinoma (HCC)

LenalidomideTargeted TherapyImmune Checkpoint Inhibitors

Shunda Du32 participants1 site · ChinaCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Phase 2Prostate Cancer Metastatic

PembrolizumabCarboplatinCabazitaxel

Fundacion Oncosur42 participants1 site · SpainCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma

PembrolizumabAldesleukin

National Cancer Institute (NCI)78 participants1 site · United StatesCompletes Sep 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2Hematological Malignancies

Talquetamab

Janssen Research & Development, LLC510 participants78 sites · United States, Belgium, ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Phase 2Breast CancerAdjuvant TreatmentEarly Stage Breast Cancer

SwitchGuideline Directed Intervention (GDI)

Dartmouth-Hitchcock Medical Center62 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

1–15 of 6,328